Janux Therapeutics, Inc.JANXNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
21.87%
↑ 187% above average
Average (22q)
-25.03%
Historical baseline
Range
High:31.44%
Low:-173.73%
Volatility
-819.6%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 21.87% |
| Q2 2025 | -29.29% |
| Q1 2025 | -20.24% |
| Q4 2024 | 19.03% |
| Q3 2024 | -159.31% |
| Q2 2024 | 31.44% |
| Q1 2024 | -24.94% |
| Q4 2023 | -2.05% |
| Q3 2023 | 23.79% |
| Q2 2023 | -2.30% |
| Q1 2023 | -11.03% |
| Q4 2022 | -1.35% |
| Q3 2022 | -4.41% |
| Q2 2022 | -27.46% |
| Q1 2022 | -0.39% |
| Q4 2021 | -23.73% |
| Q3 2021 | -74.39% |
| Q2 2021 | -173.73% |
| Q1 2021 | -38.01% |
| Q4 2020 | -31.77% |
| Q3 2020 | -13.56% |
| Q2 2020 | -33.90% |
| Q1 2020 | 0.00% |